CN101199676B - Kangxin tea - Google Patents

Kangxin tea Download PDF

Info

Publication number
CN101199676B
CN101199676B CN2007100099873A CN200710009987A CN101199676B CN 101199676 B CN101199676 B CN 101199676B CN 2007100099873 A CN2007100099873 A CN 2007100099873A CN 200710009987 A CN200710009987 A CN 200710009987A CN 101199676 B CN101199676 B CN 101199676B
Authority
CN
China
Prior art keywords
tea
radix
medicine
rhizoma atractylodis
salviae miltiorrhizae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007100099873A
Other languages
Chinese (zh)
Other versions
CN101199676A (en
Inventor
周鑫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN2007100099873A priority Critical patent/CN101199676B/en
Publication of CN101199676A publication Critical patent/CN101199676A/en
Application granted granted Critical
Publication of CN101199676B publication Critical patent/CN101199676B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to a medical preparation containing plant material resultant of reaction, in particular to a hear-recovery tea preparation for treating arrhythmia. The technical proposal of the invention is that the tea is prepared into medicine by the ingredients with weight ratio as follows: Radix Salviae Miltiorrhizae 8-10g, Radix Polygalae 5-8g, hawthorn 5-8g, Semen Cassiae 3-5g, Rhizoma Atractylodis Macrocephalae 5-8g, Pueraria lobata 5-8g, Radix Glycyrrhizae 3-5g and green tea 3-5g. The invention has the advantages that based on the theory of homology of medicine and food, treating and nourishing, the heart-recovery tea is developed combining integral control and special prescription. Clinical observations show that the invention has the advantages of safety and convenience, evident effect and easy insisting on and has the effects of preventing complication. The invention is acted on the arrhythmia patients in the way of <tea therapy>, and can effectively eliminate the clinical symptoms and substitute the traditional oral medicine; therefore the invention is worthy of promotion and application.

Description

Kangxin tea
Technical field
The present invention relates to contain the medicinal preparation that derives from the vegetable material product, especially belong to the ARR Kangxin tea medicinal tea of a kind of treatment.
Background technology
Arrhythmia is all pace-makings and the conduction abnormalities of heart.It can betide various organic heart diseasies, wherein with coronary heart disease, rheumatic valvular heart disease, cardiomyopathy, myocarditis for seeing more.Its clinical manifestation differs, and the lighter can not have sense of discomfort, or even had palpitation, leaks the sense of fighting, and weight person has blood pressure drops, faintness, tic, angina pectoris or heart failure etc.If can the clear and definite cause of disease, answer the active treatment primary disease, note correcting and trigger or follow factor, like hypotension, hypokalemia, hypomagnesemia, rhythm of the heart failure etc.Avoid too much or unnecessary anti-arrhythmic to use, in order to avoid its arrhythogenic side effect.Arrhythmia is common cardiovascular disease or complication.It is of a great variety, and the cause of disease is complicated, and its mortality, potential mortality all can cause has influence in various degree to heart, also is the principal element of contemporary cardiovascular disease high mortality.At present, still not having a kind of effective medicine for the arrhythmia person treats.
Summary of the invention
The object of the present invention is to provide a kind of easy, economical, have no side effect and treat arrhythmia Kangxin tea medicinal tea evident in efficacy.
The technical scheme that the present invention taked is: it is that Chinese crude drug by following weight ratio is made into:
Radix Salviae Miltiorrhizae 8-10g Radix Polygalae 5-8g Fructus Crataegi 5-8g Semen Cassiae 3-5g
Rhizoma Atractylodis Macrocephalae 5-8g Radix Puerariae 5-8g Radix Glycyrrhizae 3-5g green tea 3-5g.
Beneficial effect of the present invention is: the present invention is based on the theory of " integration of edible and medicinal herbs, doctor support in like manner ", integral body regulation and control and specially good effect side's medicine are combined develop the Kangxin tea medicinal tea.It selects the pure Chinese crude drug of the Nature, with Radix Salviae Miltiorrhizae: stasis-dispelling and pain-killing; Radix Polygalae: eliminating phlegm for diminishing swelling; Radix Puerariae, Semen Cassiae: clearing away heat and promoting production of body fluid; Radix Glycyrrhizae, Fructus Crataegi, the Rhizoma Atractylodis Macrocephalae: invigorating the spleen and benefiting QI, circulation of qi promoting dissipating blood stasis.Full side's combined effect, coordinating YIN and YANG, smooth and easy QI and blood, with reach promoting blood circulation to restore menstrual flow, benefiting QI and nourishing blood, the purpose of the Fructus Alpiniae Oxyphyllae of calming the nerves.The present invention shows through clinical observation: have safe and simple, evident in efficacy, be easy to adhere to, and can play the effect of complication prevention.Its form with " tea treatment " acts on arrhythmia person can effectively eliminate clinical symptoms, and replace traditional oral medication, is worthy of popularization.
Theory of Chinese medical science is inquired into: the traditional Chinese medical science thinks that arrhythmia belongs to categories such as Chinese medicine " cardiopalmus ", " palpitation with fear ", " severe palpitation ", " dizzy ", " faintness ", " asthenia ".Its disease is to invade because of evil poison is outer, and the consumption impairment of QI is cloudy, and blood is not sought network and QI and blood deficiency, due to the imbalance of YIN and YANG.Though in motherland's medical literature, there is not ARR name of disease, the regularly intermittent pulse that arrhythmia occurs is thought in the record of existing " intermittent pulse indicating severe weakness of QI, thready pulse indicating deficiency of QI; hesitant pulse indicating precordial pain " in " element ask arteries and veins want precise and tiny opinion ", is because visceral-qi is weak; Thready pulse is by due to the deficiency of vital energy, and is not smooth if arteries and veins comes, often with pained.
Medicine of the present invention is made up of pure Chinese crude drugs such as Radix Salviae Miltiorrhizae, Radix Polygalae, Fructus Crataegi, Semen Cassiae, the Rhizoma Atractylodis Macrocephalae, Radix Puerariae, Radix Glycyrrhizae, green tea, and adopts conventional modern Chinese medicine processing technology to process bag tea.Get one bag of medicated tea boiling water during use and brew for tea and drink frequently, until dark brown thin out.Its form with " tea treatment " acts on arrhythmia person can effectively eliminate clinical symptoms, reaches the purpose of disease preventing and treating.
The specific embodiment
Concrete formulation Example of the present invention is following:
Embodiment 1: it is that Chinese crude drug by following weight ratio is made into:
Radix Salviae Miltiorrhizae 8g Radix Polygalae 5g Fructus Crataegi 5g Semen Cassiae 3g
Rhizoma Atractylodis Macrocephalae 5g Radix Puerariae 5g Radix Glycyrrhizae 3g green tea 3g.
Embodiment 2: it is that Chinese crude drug by following weight ratio is made into:
Radix Salviae Miltiorrhizae 10g Radix Polygalae 8g Fructus Crataegi 8g Semen Cassiae 5g
Rhizoma Atractylodis Macrocephalae 8g Radix Puerariae 8g Radix Glycyrrhizae 5g green tea 5g.
Embodiment 3: it is that Chinese crude drug by following weight ratio is made into:
Radix Salviae Miltiorrhizae 9g Radix Polygalae 6g Fructus Crataegi 6g Semen Cassiae 4g
Rhizoma Atractylodis Macrocephalae 6g Radix Puerariae 6g Radix Glycyrrhizae 4g green tea 4g.
Embodiment 4: it is that Chinese crude drug by following weight ratio is made into:
Radix Salviae Miltiorrhizae 9g Radix Polygalae 7g Fructus Crataegi 7g Semen Cassiae 4g
Rhizoma Atractylodis Macrocephalae 7g Radix Puerariae 7g Radix Glycyrrhizae 4g green tea 4g.
The present invention is made up of pure Chinese crude drugs such as Radix Salviae Miltiorrhizae, Radix Polygalae, Fructus Crataegi, Semen Cassiae, the Rhizoma Atractylodis Macrocephalae, Radix Puerariae, Radix Glycyrrhizae, green tea, adopts conventional modern Chinese medicine processing technology, through cut into slices, pulverize, mix homogeneously, the tea bag inner packing of packing into becomes medicated tea.
Get one bag of medicated tea boiling water when the present invention uses and brew, three bags of every days.It is regardless of the period and drinks frequently for tea, until dark brown thin out.
Therapeutic outcome of the present invention:
With the result that detects electrocardiogram or 24h ambulatory electrocardiogram before and after the treatment as criterion of therapeutical effect.
Cure: clinical symptom remission, electrocardiogram recover normal;
Produce effects: clinical symptoms is clearly better, and electrocardiogram improves obviously;
Effectively: clinical symptoms is improved slowly, and electrocardiogram has improvement slightly;
Invalid: clinical symptoms and electrocardiogram do not have improvement or increase the weight of.
Below all medical records all from prosperous subhealth state institute of week, case is collected and to be lasted for two years.80 routine arrhythmia persons, male 43 examples, women 37 examples; The oldest person 79 years old, age reckling 4 years old, 39.5 years old mean age; The elder of medical history 17 years, the shortest person half a year, average medical history 11 years.All cases are all made electrocardiogram and 24h dynamic ecg recordings examination.According to ARR clinical diagnosis standard prompts: suffer from coronary disease patient 38 examples, arrhythmia person's 19 examples due to hypertensive cardiopathy person 11 examples, rheumatic heart disease person's 5 examples, myocarditis person's 7 examples, other causes of disease.
All patients Kangxin tea medicinal tea are after 1 year, change as criterion of therapeutical effect according to clinical symptoms and sign and electrocardio.Cure 58 examples among the 80 routine patients, account for 75%; Produce effects 10 examples account for 12.5%; Effective 7 examples account for 8.75%; Invalid 5 examples account for 3.75%; Total effective rate is 96.25%.

Claims (5)

1. Kangxin tea is characterized in that: it is that Chinese crude drug by following weight ratio is made into:
Radix Salviae Miltiorrhizae 8-10g Radix Polygalae 5-8g Fructus Crataegi 5-8g Semen Cassiae 3-5g
Rhizoma Atractylodis Macrocephalae 5-8g Radix Puerariae 5-8g Radix Glycyrrhizae 3-5g green tea 3-5g.
2. according to the said Kangxin tea of claim 1, it is characterized in that: it is that Chinese crude drug by following weight ratio is made into:
Radix Salviae Miltiorrhizae 8g Radix Polygalae 5g Fructus Crataegi 5g Semen Cassiae 3g
Rhizoma Atractylodis Macrocephalae 5g Radix Puerariae 5g Radix Glycyrrhizae 3g green tea 3g.
3. according to the said Kangxin tea of claim 1, it is characterized in that: it is that Chinese crude drug by following weight ratio is made into:
Radix Salviae Miltiorrhizae 10g Radix Polygalae 8g Fructus Crataegi 8g Semen Cassiae 5g
Rhizoma Atractylodis Macrocephalae 8g Radix Puerariae 8g Radix Glycyrrhizae 5g green tea 5g.
4. according to the said Kangxin tea of claim 1, it is characterized in that: it is that Chinese crude drug by following weight ratio is made into:
Radix Salviae Miltiorrhizae 9g Radix Polygalae 6g Fructus Crataegi 6g Semen Cassiae 4g
Rhizoma Atractylodis Macrocephalae 6g Radix Puerariae 6g Radix Glycyrrhizae 4g green tea 4g.
5. according to the said Kangxin tea of claim 1, it is characterized in that: it is that Chinese crude drug by following weight ratio is made into:
Radix Salviae Miltiorrhizae 9g Radix Polygalae 7g Fructus Crataegi 7g Semen Cassiae 4g
Rhizoma Atractylodis Macrocephalae 7g Radix Puerariae 7g Radix Glycyrrhizae 4g green tea 4g.
CN2007100099873A 2007-12-11 2007-12-11 Kangxin tea Expired - Fee Related CN101199676B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2007100099873A CN101199676B (en) 2007-12-11 2007-12-11 Kangxin tea

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2007100099873A CN101199676B (en) 2007-12-11 2007-12-11 Kangxin tea

Publications (2)

Publication Number Publication Date
CN101199676A CN101199676A (en) 2008-06-18
CN101199676B true CN101199676B (en) 2012-04-18

Family

ID=39515158

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007100099873A Expired - Fee Related CN101199676B (en) 2007-12-11 2007-12-11 Kangxin tea

Country Status (1)

Country Link
CN (1) CN101199676B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105166186A (en) * 2015-10-09 2015-12-23 黄岚 Health-care tea with functions of spleen invigorating and qi supplementing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1895541A (en) * 2006-06-08 2007-01-17 上海玉森新药开发有限公司 Chinese-medicinal composition for treating arrhythmia
CN1931354A (en) * 2005-09-16 2007-03-21 高松寿 Arrhythmia treating Chinese medicine prepn and its prepn process

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1931354A (en) * 2005-09-16 2007-03-21 高松寿 Arrhythmia treating Chinese medicine prepn and its prepn process
CN1895541A (en) * 2006-06-08 2007-01-17 上海玉森新药开发有限公司 Chinese-medicinal composition for treating arrhythmia

Also Published As

Publication number Publication date
CN101199676A (en) 2008-06-18

Similar Documents

Publication Publication Date Title
CN100382839C (en) Chinese-medicinal composition for treating coronary heart disease
CN100435831C (en) Preparation for treating high blood pressure, high blood fat, obesity, and climacteric syndrome, and preparation method
CN102988750A (en) TCM (Traditional Chinese medicine) composition for treating diabetes and preparation method thereof
CN101843661B (en) Chinese medicament for treating angina
CN101095768B (en) Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age
CN102380032A (en) Traditional Chinese medicine for treating diabetic heart disease
CN101199676B (en) Kangxin tea
CN108355055A (en) A kind of pharmaceutical composition for treating hypertension
CN102988747B (en) Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof
CN100339119C (en) Traditional Chinese medicine prepns. for treating diabete
CN104758439A (en) Traditional Chinese medicine composition for treating thoracic obstruction
CN109078157A (en) A kind of anti-tumor drug and preparation method thereof
CN103385963A (en) Chinese medicine preparation for treating angina pectoris caused by coronary heart disease
CN103212041A (en) Chinese medicinal composition treating coronary heart disease
CN1239196C (en) Nutrient healthy powder for decreasing blood sugar and resolving stagnation
CN101411824B (en) Medicament for treating galactocele
CN101411831B (en) Medicament for treating low fever
CN101843878B (en) Chinese medicament for treating diabetic cardiopathy
CN102389494A (en) Chinese medicine for treating diabetic heart diseases
CN101843753B (en) Chinese medicament for treating angina
CN101843712A (en) Chinese medicament for treating angina
CN101850054B (en) Chinese medicament for treating diabetic heart diseases
CN103655917B (en) A kind of Chinese medicine for the treatment of cardiovascular and cerebrovascular disease
CN112426505A (en) Chinese patent medicine for treating perimenopausal cardiac neurosis
CN101850034B (en) Chinese medicament for treating angina

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120418

Termination date: 20121211